Table 2.
Subgroup analysis of DCR
| Subgroup analysis | Total no of studies | Treatment group
|
Control group
|
RR (95% CI) of DCR | ||
|---|---|---|---|---|---|---|
| Total no of patients | Subjects (SD + PR + CR) | Total no of patients | Subjects (SD + PR + CR) | |||
| Tumor type | ||||||
| GC | 2 | 309 | 114 | 144 | 13 | 4.10 (2.39, 7.02) |
| HCC | 2 | 40 | 27 | 42 | 20 | 1.54 (0.66, 3.60) |
| NSCLC | 3 | 137 | 85 | 141 | 51 | 1.71 (0.81, 3.60) |
| Line | ||||||
| Second line | 2 | 47 | 23 | 96 | 40 | 1.28 (0.60, 2.76) |
| Third line | 3 | 399 | 176 | 189 | 24 | 3.39 (2.42, 4.95) |
| Apatinib dose | ||||||
| 850 mg | 2 | 309 | 114 | 144 | 13 | 4.10 (2.39, 7.02) |
| 750 mg | 1 | 90 | 62 | 45 | 11 | 2.82 (1.66, 4.80) |
| 500 mg | 2 | 40 | 29 | 42 | 22 | 1.40 (0.79, 2.46) |
Abbreviations: CR, complete remission; PR, partial remission; SD, stable disease; DCR, disease control rate; GC, gastric cancer; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer.